Pre-Made Verpasep Caltespen biosimilar, Fusion Protein: Recombinant therapeutic protein targeting HspE7(Mycobacterium bovis HSP65-HBV E7) fused with chaperonin 2 (HSP65 from Mycobacterium bovis) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Verpasep Caltespen biosimilar, Fusion Protein: Recombinant therapeutic protein targeting HspE7(Mycobacterium bovis HSP65-HBV E7) fused with chaperonin 2 (HSP65 from Mycobacterium bovis) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
HspE7 is a recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from?Mycobacterium bovis, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers. E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes. It is being developed by StressGen Biotechnologies Corp.
HspE7 works by efficiently delivering the E7 antigen to dendritic cells, which have a natural affinity for Hsp. Dendritic cells are known to be the most potent cells in the body for triggering immune responses. Coupling E7 to Hsp takes advantage of the Hsp receptors that dendritic cells express on their surface to introduce E7, as part of a larger fusion protein, into the dendritic cells.
Verpasep caltespen is a recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers. E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes.
| Products Name (INN Index) | Pre-Made Verpasep Caltespen biosimilar, Fusion Protein: Recombinant therapeutic protein targeting HspE7(Mycobacterium bovis HSP65-HBV E7) fused with chaperonin 2 (HSP65 from Mycobacterium bovis) |
|---|---|
| INN Name | verpasep caltespen |
| Target | HspE7(Mycobacterium bovis HSP65-HBV E7) |
| Format | Fusion Protein |
| Derivation | Mycobacterium tuberculosis variant bovis Alphapapillomavirus 9 |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – Mycobacterium tuberculosis variant bovis chaperonin 2 (HSP65 from Mycobacterium bovis) – Alphapapillomavirus 9 E7 HPV16 |
| VD LC | Fusion – Mycobacterium tuberculosis variant bovis chaperonin 2 (HSP65 from Mycobacterium bovis) – Alphapapillomavirus 9 E7 HPV16 |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Nventa Biopharmaceuticals Corporation |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | HspE7(Mycobacterium bovis HSP65-HBV E7) |
| Package |
